[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573344":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":24,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":24,"overallStatus":43,"whyStopped":24,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin","EXPERIMENTAL","12 week treatment with 10mg empagliflozin daily",[13],"Drug: Empagliflozin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","12 week treatment with 10mg placebo daily",[19],"Drug: Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":30,"role":31},"Jaume Padilla Parellada, PhD","Harry S. Truman Memorial, Columbia, MO","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":24,"email":36},"CONTACT","(573) 814-6552","jaume.padillaparellada@va.gov",{"name":38,"role":34,"phone":39,"phoneExt":24,"email":40},"Katherine M Burr","(573) 814-6550","Katherine.Burr@va.gov",[42],{"facility":30,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Columbia","Missouri","65201-5275","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-92.33407,38.95171,{"lat":53,"lon":52},[56,58],{"name":29,"role":34,"phone":57,"phoneExt":24,"email":36},"573-814-6552",{"name":29,"role":31,"phone":24,"phoneExt":24,"email":24},{"type":60,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[62],{"name":63,"class":64},"University of Missouri-Columbia","OTHER","100573344","phase-2-arterial-destiffening-effects-of-sglt2-inhibition-in-veterans-with-obesity-100573344",false,"NCT06745063","Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity","EMPA","Inclusion Criteria:\n\n* Body mass index (BMI) 30-45 kg\u002Fm2\n* 30-60 years of age at randomization\n* Evidence of arterial stiffening (defined as Carotid femoral PWV\\>age-predicted) at screening visit (PMID: 20530030)\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Diabetes mellitus\n* Uncontrolled hypertension (\\>180\u002F90mmHg) or systolic \\\u003C100mmHg at screening visit\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke\n* Diagnosis of chronic kidney disease\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Excessive alcohol consumption (\\>14 drinks\u002Fweek for men, \\>7 drinks\u002Fweek for women)\n* Use of GLP-1 analogs or SGLT2 inhibitors\n* Use of hormone replacement therapy\n* Use of pharmacological therapy for weight loss\n* Body weight changes \\>10% within the past 6 months\n* History of hypersensitivity to nitrates\n* History of ketoacidosis\n* History of recurrent UTIs or mycotic genital infections\n* Use of anticoagulants\n* Change in anti-hypertensive medication regimen (if in use) during the last 90 days\n* Pregnancy",true,"ALL","30 Years","60 Years",{"count":77,"type":78},50,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.",[84,85],"Obesity","Vascular Health","2025-11-13",{"date":88,"type":89},"2025-11-14","ACTUAL",{"date":91,"type":89},"2025-05-30",{"date":93,"type":78},"2029-12-31",{"name":5,"class":6},1]